John Souglakos

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Axel Grothey, Alberto Sobrero, Anthony F. Shields et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 670 citations

Medicine, Oncology, Pharmacology +17

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Jan Franko, Qian Shi, Jeffrey P. Meyers et al. · The Lancet Oncology · 2016 · 660 citations

Medicine, Biostatistics, Oncology +11

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

John Souglakos, Juliet Philips, R Wang et al. · British Journal of Cancer · 2009 · 320 citations · Full text

Medicine, Genetics, Oncology +17